The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Brazil vaccinations start nationwide as country faces vaccine ingredient shortfall

Mon, 18th Jan 2021 11:47

(Adds concerns about delayed imports, Bolsonaro comments)

By Eduardo Simões

SAO PAULO, Jan 18 (Reuters) - Brazil kicked off a nationwide
COVID-19 immunization program on Monday by distributing doses of
a vaccine from China's Sinovac Biotech following an
emergency use authorization, although the pace of vaccination
will depend on delayed imports.

After weeks of setbacks, many Brazilians cheered the first
wave of inoculations, from bustling clinics in Sao Paulo to a
spectacular shot planned at the foot of the Christ Redeemer
statue overlooking Rio de Janeiro.

The Health Ministry gave states the green light to start
immunizing at 5 p.m. (2000 GMT), although some officials lost no
time in starting the vaccinations.

Minutes after federal health agency Anvisa approved the
Sinovac vaccine on Sunday, Monica Calazans, a 54-year-old nurse
in Sao Paulo, became the first person to be inoculated in the
country, as Sao Paulo Governor Joao Doria looked on.

President Jair Bolsonaro, a COVID-19 skeptic who has refused
to take a vaccine himself, had faced fierce criticism for the
lack of immunization in Brazil, which has lost more than 200,000
lives to COVID-19 – the pandemic's worst death toll outside the
United States.

On Sunday, Anvisa approved emergency use of the Sinovac
vaccine and one from AstraZeneca Plc, although a hurried
plan to get 2 million doses of the AstraZeneca vaccine was
hamstrung by a lack of export approval from India.

That was one of several hurdles threatening to slow Brazil's
already lagging immunization efforts, as local manufacturing
partners for both vaccine makers wait on active ingredients from
abroad in order to fill and finish doses for distribution.

The Butantan Institute run by Sao Paulo state needs another
shipment of Sinovac's ingredients by the end of the month in
order to hit its target of 46 million doses by April, the head
of the institute told a news conference.

The federally-funded Fiocruz biomedical center in Rio de
Janeiro is still awaiting its first shipment of ingredients for
AstraZeneca's vaccine, pending Chinese export approval.

Health Minister Eduardo Pazuello scolded Doria on Sunday for
what he called an illegal "marketing ploy" for giving the green
light to begin vaccinations in Sao Paulo prior to the official
rollout.

Bolsonaro, who had taunted Doria over the disappointing 50%
efficacy of the Sinovac vaccine in Brazilian trials, added an
indirect criticism on Monday.

"So it's been approved for use in Brazil. It is Brazil's
vaccine. It doesn't belong to any governor," he told supporters
outside the presidential palace.

(Reporting by Eduardo Simoes
Additional reporting by Lisandra Paraguassu and Sabrina Valle
Editing by Brad Haynes and Bill Berkrot)

More News
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.